Merck & Co., Inc. MRK
We take great care to ensure that the data presented and summarized in this overview for Merck & Co., Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRK
View all-
Vanguard Group Inc Valley Forge, PA251MShares$23.2 Billion0.45% of portfolio
-
Black Rock Inc. New York, NY207MShares$19.1 Billion0.59% of portfolio
-
State Street Corp Boston, MA121MShares$11.2 Billion0.49% of portfolio
-
Wellington Management Group LLP Boston, MA80.7MShares$7.45 Billion1.51% of portfolio
-
Geode Capital Management, LLC Boston, MA61.2MShares$5.64 Billion0.48% of portfolio
-
Morgan Stanley New York, NY44.2MShares$4.08 Billion0.32% of portfolio
-
Bank Of America Corp Charlotte, NC36.4MShares$3.36 Billion0.31% of portfolio
-
Norges Bank Oslo, Q835MShares$3.23 Billion0.47% of portfolio
-
Northern Trust Corp Chicago, IL31.4MShares$2.89 Billion0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY27.1MShares$2.5 Billion0.22% of portfolio
Latest Institutional Activity in MRK
Top Purchases
Top Sells
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Transactions at MRK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
8,500
-21.68%
|
$714,000
$84.09 P/Share
|
|
Feb 13
2025
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Open market or private sale
|
Direct |
6,000
-19.92%
|
$510,000
$85.34 P/Share
|
|
Feb 08
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
6,404
-14.04%
|
$557,148
$87.28 P/Share
|
|
Feb 08
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
13,002
+22.18%
|
$1,131,174
$87.28 P/Share
|
|
Feb 06
2025
|
Inge G Thulin Director |
BUY
Open market or private purchase
|
Direct |
2,832
+49.13%
|
$249,216
$88.25 P/Share
|
|
Feb 06
2025
|
Cristal N Downing Chief Comm. & Public Afrs Ofcr |
SELL
Open market or private sale
|
Direct |
2,361
-24.99%
|
$207,768
$88.76 P/Share
|
|
Feb 05
2025
|
Douglas M Baker Jr Director |
BUY
Open market or private purchase
|
Direct |
15,000
+48.39%
|
$1,320,000
$88.5 P/Share
|
|
Jan 27
2025
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,586
+26.94%
|
$250,842
$97.94 P/Share
|
|
Jan 27
2025
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,246
+25.38%
|
$993,862
$97.94 P/Share
|
|
Jan 27
2025
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,423
+31.5%
|
$2,466,031
$97.94 P/Share
|
|
Jan 27
2025
|
Caroline Litchfield EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
23,432
+23.97%
|
$2,272,904
$97.94 P/Share
|
|
Jan 27
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Grant, award, or other acquisition
|
Direct |
8,664
+20.99%
|
$840,408
$97.94 P/Share
|
|
Jan 27
2025
|
Cristal N Downing Chief Comm. & Public Afrs Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
9,446
+50.0%
|
$916,262
$97.94 P/Share
|
|
Jan 27
2025
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,621
+29.07%
|
$3,164,237
$97.94 P/Share
|
|
Jan 27
2025
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
95,275
+17.68%
|
$9,241,675
$97.94 P/Share
|
|
Jan 27
2025
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
25,438
+12.44%
|
$2,467,486
$97.94 P/Share
|
|
Jan 27
2025
|
Chirfi Guindo Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,158
+28.94%
|
$2,731,326
$97.94 P/Share
|
|
Jan 27
2025
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
28,136
+26.32%
|
$2,729,192
$97.94 P/Share
|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,412
-30.13%
|
$2,002,380
$115.2 P/Share
|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,901
+38.97%
|
$4,243,615
$115.2 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 17.8K shares |
|---|---|
| Grant, award, or other acquisition | 289K shares |
| Exercise of conversion of derivative security | 84.1K shares |
| Payment of exercise price or tax liability | 40.5K shares |
|---|---|
| Open market or private sale | 16.9K shares |